dalcetrapib
Phase 3Small molecule
Rochedalcetrapib is one of 48 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 3.
1
Indications
14
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Acute Coronary Syndrome
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Colcrys
Jazz PharmaceuticalsApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Leqvio
NovartisApproved
Zyloprim
Jazz PharmaceuticalsApproved
Fragmin
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Coronary Syndrome3 trials
Heart Disease3 trials
Coronary Artery Disease1 trial
Atorvastatin1 trial
5 more indications
Safety and Efficacy1 trial
Acute Lymphoblastic Leukemia1 trial
Cholesterol1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for dalcetrapib. EMBL-EBI & Wellcome Sanger Institute.
- [4]